U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug

France Nouvelles Nouvelles

U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug
France Dernières Nouvelles,France Actualités
  • 📰 Investingcom
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 53%

U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug

© Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File PhotoDespite the FDA approval, Amgen's treatment is expected to be launched in 2025 as part of a legal settlement between the two companies earlier this year to delay the entry of the therapy.Stelara, introduced in 2009, has been J&J's top-selling drug since 2019, with sales reaching $9.7 billion in 2022.

{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Investingcom /  🏆 450. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Amgen third-quarter sales rise 5%; profit up before chargeAmgen third-quarter sales rise 5%; profit up before chargeAmgen third-quarter sales rise 5%; profit up before charge
Lire la suite »

Amgen's stock hit by expectations its obesity pipeline is facing a longer waitAmgen's stock hit by expectations its obesity pipeline is facing a longer waitAmgen said data from an early and mid-stage trial of obesity drugs will come in 2024
Lire la suite »

Amgen third-quarter sales rise 5%; profit up before chargeAmgen third-quarter sales rise 5%; profit up before chargeAmgen (AMGN.O), which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.
Lire la suite »

Amgen’s stock jumps premarket after earnings beat and company again raises guidanceAmgen’s stock jumps premarket after earnings beat and company again raises guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Lire la suite »

Amgen Stock Jumps on Earnings Beat, Guidance BoostAmgen Stock Jumps on Earnings Beat, Guidance BoostThe biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.
Lire la suite »

Some Cold Medicines Don’t Work. Here’s What Doctors Recommend Instead.Some Cold Medicines Don’t Work. Here’s What Doctors Recommend Instead.With FDA advisers determining that phenylephrine is ineffective, doctors and pharmacists recommend alternatives for congestion relief
Lire la suite »



Render Time: 2025-02-27 10:11:44